본문 바로가기
KERD
논문KCI 등재

코로나바이러스 감염증-19 백신에 대한 업데이트 및 소아청소년에서의 고려사항

Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children

Kim Yae-Jean|Choi Eun Hwa|Kang Hyun Mi
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)|2021.04|Pediatric Infection and Vaccine|제28권 제1호|pp. 7-20|DOI 10.14776/piv.2021.28.e6

2

조회

0

다운로드

11

인용

0

참고문헌

키워드

COVID-19ChildSARS-CoV-2Vaccines

초록

2021년 3월 현재, 인류는 2019년 말부터 시작된 코로나바이러스 감염증-19(COVID-19)의 세계적 유행으로 인해 고통받고 있다. 2020년에는 messenger RNA (mRNA) 백신, 바이러스 벡터를 사용한 DNA 백신 등 새로운 플랫폼의 백신들이 긴급사용승인을 받았고, 이후 대규모 접종이 이루어지기 시작하였다. 본 논문에서는 현재 전 세계적으로 가장 널리 사용되고 있는 COVID-19 백신들에 대하여 그 기전을 살펴보고, 임상시험 내용을 분석하여 효능과 안전선에 대한 자료를 정리하였고, 소아청소년에 대한 백신 임상시험 상황 및 소아에서 고려할 점에 대하여 언급하였다.

Abstract

As of March 2021, humanity has been suffering from the global severe acute respiratory syndrome coronavirus 2 pandemic that began late 2019. In 2020, new vaccine platforms—including mRNA vaccines and viral vector-based DNA vaccines—have been given emergency use authorization (EUA), leading to rolling out the vaccines for global mass vaccinations. The purpose of this article is to review the currently most widely used coronavirus disease 2019 vaccines: their action mechanisms and efficacy and safety data from clinical trials that have been published to date. In addition, the current status of clinical trials in the pediatric population was summarized, and further consideration for them was discussed.

참고문헌 (60)

  1. Fraser C, "Factors that make an infectious disease outbreak controllable", Proc Natl Acad Sci U S A, 101, pp.6146~6151 (2004)
  2. Peak CM, "Comparing nonpharmaceutical interventions for containing emerging epidemics", Proc Natl Acad Sci U S A, 114, pp.4023~4028 (2017)
  3. Weber DJ, "Emerging infectious diseases : focus on infection control issues for novel coronaviruses(severe acute respiratory syndrome-CoV and Middle East respiratory syndrome-CoV), hemorrhagic fever viruses(Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1)and A(H7N9)", Am J Infect Control, 44, pp.e91~e100 (2016)
  4. Park Yoojin, "Application of Testing-Tracing-Treatment Strategy in Response to the COVID-19 Outbreak in Seoul, Korea", Journal of Korean Medical Science, 35(45), pp.1~9 (2020), 대한의학회[DOI]
  5. Haber MJ, "Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic", Emerg Infect Dis, 13, pp.581~589 (2007)
  6. "Draft landscape and tracker of COVID-19 candidate vaccines" (2021)[URL]
  7. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
  8. Naqvi AAT, "Insights into SARS-CoV-2genome, structure, evolution, pathogenesis and therapies : Structural genomics approach", Biochim Biophys Acta Mol Basis Dis, 1866, pp.165878~ (2020)
  9. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292.e6 (2020)
  10. Sternberg A, "Structural features of coronavirus SARS-CoV-2 spike protein : targets for vaccination", Life Sci, 257, pp.118056~ (2020)
  11. Huang Y, "Structural and functional properties of SARS-CoV-2 spike protein : potential antivirus drug development for COVID-19", Acta Pharmacol Sin, 41, pp.1141~1149 (2020)
  12. Tian X, "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody", Emerg Microbes Infect, 9, pp.382~385 (2020)
  13. Walsh EE, "Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
  14. Jackson LA, "An mRNA vaccine against SARS-CoV-2-Preliminary report", N Engl J Med, 383, pp.1920~1931 (2020)
  15. Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
  16. Sadoff J, "Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine", N Engl J Med, pp.NEJMoa2034~ (2021)
  17. "Status of COVID-19 vaccines within WHO EUL/PQ evaluation process" (2021)[URL]
  18. Humphreys IR, "Novel viral vectors in infectious diseases", Immunology, 153, pp.1~9 (2018)
  19. Dai L, "Viral targets for vaccines against COVID-19", Nat Rev Immunol, 21, pp.73~82 (2021)
  20. Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
  21. "Understanding messenger RNA and other SARS-CoV-2 vaccines" (2020)[URL]
  22. Corbett KS, "SARS-CoV-2mRNA vaccine design enabled by prototype pathogen preparedness", Nature, 586, pp.567~571 (2020)
  23. Corbett KS, "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates", N Engl J Med, 383, pp.1544~1555 (2020)
  24. Antrobus RD, "Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens", Mol Ther, 22, pp.668~674 (2014)
  25. Zhang C, "Adenoviral vector-based strategies against infectious disease and cancer", Hum Vaccin Immunother, 12, pp.2064~2074 (2016)
  26. Afrough S, "Immunologic dose-response to adenovirus-vectored vaccines in animals and humans: a systematic review of dose-response studies of replication incompetent adenoviral vaccine vectors when given via an intramuscular or subcutaneous route", Vaccines, 8, pp.131~ (2020)
  27. Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
  28. Baden LR, "Efficacy and safety of the mRNA-1273SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
  29. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
  30. Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine : a pooled analysis of four randomised trials", Lancet, 397, pp.881~891 (2021)
  31. Sadoff J, "Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19", N Engl J Med (2021)
  32. "COVID-19 vaccine Ad26.COV2.S sponsor briefing document" (2021)[URL]
  33. Muir KL, "Thrombotic thrombocytopenia after Ad26.COV2.S vaccination", N Engl J Med (2021)
  34. Schultz NH, "Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination", N Engl J Med (2021)
  35. Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med (2021)
  36. "AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets" (2021)[URL]
  37. "COVID-19 vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - Vaccine's benefits currently still outweigh risks - Update" (2021)[URL]
  38. Østergaard SD, "Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?", Lancet, 397, pp.1441~1443 (2021)
  39. Mahase E, "AstraZeneca vaccine : blood clots are"extremely rare"and benefits outweigh risks, regulators conclude", BMJ, 373, pp.n931~ (2021)
  40. "Resuming some pending AstraZeneca vaccinations from April 12th" (2021)[URL]
  41. "CDC recommends use of Johnson & Johnson's Janssen COVID-19 vaccine resume" (2021)[URL]
  42. "Studying the COVID-19 vaccine for children" (2021)[URL]
  43. "Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents" (2021)[URL]
  44. A COVID-19 vaccine study for children, "Moderna", Moderna, ~, pp.Kidcove Study Trial ID: NCT04796896 (2021)
  45. "A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age" (2021)[URL]
  46. "First children's COVID-19 vaccine trial open" (2021)[URL]
  47. "Johnson & Johnson expands phase 2a clinical trial of COVID-19 vaccine candidate to include adolescents" (2021)[URL]
  48. "World population prospects 2019: data query" (2021)[URL]
  49. Lu X, "SARS-CoV-2 infection in children", N Engl J Med, 382, pp.1663~1665 (2020)
  50. Han MS, "Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea", JAMA Pediatr, 175, pp.73~80 (2021)
  51. Jiehao C, "A case series of children with 2019 novel coronavirus infection : clinical and epidemiological features", Clin Infect Dis, 71, pp.1547~1551 (2020)
  52. Liu W, "Detection of COVID-19 in children in early January 2020 in Wuhan, China", N Engl J Med, 382, pp.1370~1371 (2020)
  53. Qiu H, "Clinical and epidemiological features of 36 children with coronavirus disease 2019(COVID-19)in Zhejiang, China : an observational cohort study", Lancet Infect Dis, 20, pp.689~696 (2020)
  54. Soo-Han Choi, "Epidemiology and clinical features of coronavirus disease 2019 in children", Clinical and Experimental Pediatrics, 63(4), pp.125~132 (2020), 대한소아청소년과학회
  55. Children and COVID-19: state-level data report, "American Academy of Pediatrics", AAP, ~ (2021)
  56. "2019-20 season's pediatric flu deaths tie high mark set during 2017-18 season" (2021)[URL]
  57. "Children likely the 'leading edge' in spread of COVID-19 variants" (2021)[URL]
  58. Klass P, "Vaccinating children against COVID-19-The lessons of measles", N Engl J Med, 384, pp.589~591 (2021)
  59. Anderson EJ, "Warp speed for COVID-19vaccines: Why are children stuck in neutral?", Clin Infect Dis, pp.ciaa1425~ (2020)
  60. Wong BLH, "Should children be vaccinated against COVID-19 now?", Arch Dis Child (2021)

관련 논문AI추천

COVID-19 백신의 소아 접종: 우리는 무엇을 준비해야 하는가?박소연(재) 국가생명윤리정책원 · 생명, 윤리와 정책2021 · 제5권 제2호5-11세 소아에서 코로나19 백신의 효능 및 안전성에 대한 체계적 문헌고찰유수연, 정채림, 최미영, 최수한, 최영준대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호소아청소년 코로나바이러스감염증-19의 치료: 치료 약제를 중심으로윤기욱, 최수한, 최재홍대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호소아청소년에서 Coronavirus Disease 2019 백신에 대한 이상 반응이은, 김경훈, 김민지, 양현종, 염혜영, 이미희, 이용주대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2022 · 제10권 제1호국내 5-11세 소아의 코로나19 백신 접종에 대한 델파이 연구이영화, 최영준, 최재홍대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호해외 주요 국가의 5-11세 소아 코로나19 예방접종 정책 동향문지현, 최영준, 최윤영대한소아감염학회 · Pediatric Infection and Vaccine2022 · 제29권 제1호

이 간행물의 다른 논문 (5건)

코로나바이러스감염증-19: 소아청소년의 임상 경과가 성인에 비하여 양호한 이유김동현, 곽병옥pp. 1-6Opsonophagocytic Antibodies of Intravenous Immunoglobulin Preparations against Seven Streptococcus agalactiae SerotypesCha Jihei, 이지현, Kim Kyung-Hyo, 김한울pp. 21-30확진된 소아청소년 결핵에서 인터페론감마 분비검사의 진단적 가치Kim Kyu Ho, Kang Ji-Man, Ahn Jong Gyunpp. 31-41A Case with Multiple Fungal Coinfections in a Patient who Presented with Pancoast SyndromeYoo So-Young, Jeon Tae Yeon, Kim Dongsub, 유건희, Huh Hee Jae, Lee Nam Yong, Cho Hee Won, 구홍회, 김예진, Choi Joon-sik, Jin Hyungsuk, Han Joungho, Ma Youngeunpp. 42-48단순 포진 감염으로 오인된 자매에서 발생한 소아 얼굴 백선 2 례Kang Ji-Man, Hwang JiHoon, Ahn Jong Gyunpp. 49-56
원문 보기